Effectiveness of nalbuphine, a κ-opioid receptor agonist and μ-opioid receptor antagonist, in the inhibition of INa, IK(M), and IK(erg) unlinked to interaction with opioid receptors

被引:11
|
作者
Liu, Yuan-Yuarn [1 ]
Hsiao, Hung-Tsung [2 ]
Wang, Jeffery C. -F. [2 ]
Liu, Yen-Chin [2 ]
Wu, Sheng-Nan [3 ,4 ]
机构
[1] Kaohsiung Vet Gen Hosp, Div Trauma, Dept Emergency, Kaohsiung, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Anesthesiol, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan
[4] Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 70101, Taiwan
关键词
delayed-rectifier K+ current; erg-mediated K+ current; hippocampal neuron; M-type K+ current; nalbuphine; opioid receptor; voltage-gated Na+ current; CHANNELS; CELLS; TEFLUTHRIN; ACTIVATION; MORPHINE; ALPHA; STAGE;
D O I
10.1002/ddr.21568
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nalbuphine (NAL) is recognized as a mixer with the kappa-opioid receptor agonist and the mu-opioid receptor antagonist. However, whether this drug causes any modifications in neuronal ionic currents is unclear. The effects of NAL on ionic currents in mHippoE-14 hippocampal neurons were investigated. In the whole-cell current recordings, NAL suppressed the peak amplitude of voltage-gated Na+ current (I-Na) with an IC50 value of 1.9 mu M. It shifted the steady-state inactivation curve of peak I-Na to the hyperpolarized potential, suggesting that there is the voltage dependence of NAL-mediated inhibition of peak I-Na. In continued presence of NAL, subsequent application of either dynorphin A(1-13) (1 mu M) or naloxone (30 mu M) failed to modify its suppression of peak I-Na. Tefluthrin (Tef; 10 mu M), a pyrethroid known to activate I-Na, increased peak I-Na with slowed current inactivation; however, further application of NAL suppressed Tef-mediated suppression of peak I-Na followed by an additional slowing of current inactivation. In addition, NAL suppressed the amplitude of M-type K+ current [I-K(M)] with an IC50 value of 5.7 mu M, while it slightly suppressed erg-mediated and delayed-rectifier K+ currents. In the inside-out current recordings, NAL failed to modify the activity of large-conductance Ca2+-activated K+ channels. In differentiated NG108-15 neuronal cells, NAL also suppressed the peak I-Na, and subsequent addition of Tef reversed NAL-induced suppression of I-Na. Our study highlights the evidence that in addition to modulate opioid receptors, NAL has the propensity to interfere with ionic currents including I-Na and I-K(M), thereby influencing the functional activities of central neurons.
引用
收藏
页码:846 / 856
页数:11
相关论文
共 50 条
  • [1] Pentapeptides Displaying μ Opioid Receptor Agonist and δ Opioid Receptor Partial Agonist/Antagonist Properties
    Purington, Lauren C.
    Pogozheva, Irina D.
    Traynor, John R.
    Mosberg, Henry I.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (23) : 7724 - 7731
  • [2] Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/μ opioid receptor antagonist
    Wade, P. R.
    Palmer, J. M.
    McKenney, S.
    Kenigs, V.
    Chevalier, K.
    Moore, B. A.
    Mabus, J. R.
    Saunders, P. R.
    Wallace, N. H.
    Schneider, C. R.
    Kimball, E. S.
    Breslin, H. J.
    He, W.
    Hornby, P. J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 167 (05) : 1111 - 1125
  • [3] DIFFERENTIAL INTERACTION OF THE OPIOID RECEPTOR WITH AGONIST AND ANTAGONIST MORPHINAN DERIVATIVES
    LEMAIRE, S
    BELLEAU, B
    FASEB JOURNAL, 1988, 2 (05): : A1391 - A1391
  • [4] RECOGNITION OF OPIOID AGONIST AND ANTAGONIST IN THE OPIOID RECEPTOR-BINDING SITE
    NOZAKI, M
    NIWA, M
    HASEGAWA, J
    IMAI, E
    HORI, M
    FUJIMURA, H
    LIFE SCIENCES, 1982, 31 (12-1) : 1339 - 1342
  • [5] Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy μ opioid receptor agonist and a δ opioid receptor antagonist
    Mada, Sanjana
    Gerak, Lisa R.
    Soyer, Amelie
    Maguire, David R.
    Hu, Zehua
    Minervini, Vanessa
    Cunningham, Christopher W.
    France, Charles P.
    PSYCHOPHARMACOLOGY, 2020, 237 (12) : 3591 - 3602
  • [6] Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist
    Sanjana Mada
    Lisa R. Gerak
    Amélie Soyer
    David R. Maguire
    Zehua Hu
    Vanessa Minervini
    Christopher W. Cunningham
    Charles P. France
    Psychopharmacology, 2020, 237 : 3591 - 3602
  • [7] Heterodimerization of opioid receptor-like 1 and μ-opioid receptors impairs the potency of μ receptor agonist
    Wang, HL
    Hsu, CY
    Huang, PC
    Kuo, YL
    Li, AH
    Yeh, TH
    Tso, AS
    Chen, YL
    JOURNAL OF NEUROCHEMISTRY, 2005, 92 (06) : 1285 - 1294
  • [8] Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands
    Mosberg, Henry I.
    Yeomans, Larisa
    Harland, Aubrie A.
    Bender, Aaron M.
    Sobczyk-Kojiro, Katarzyna
    Anand, Jessica P.
    Clark, Mary J.
    Jutkiewicz, Emily M.
    Traynor, John R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (05) : 2139 - 2149
  • [9] In vivo effects of -opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration
    Anand, Jessica P.
    Kochan, Kelsey E.
    Nastase, Anthony F.
    Montgomery, Deanna
    Griggs, Nicholas W.
    Traynor, John R.
    Mosberg, Henry I.
    Jutkiewicz, Emily M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (11) : 2013 - 2027
  • [10] A Novel Approach to Safer Analgesics: Mu Opioid Receptor Agonist & Delta Opioid Receptor Antagonist Peptidomimetics
    Fernandez, Thomas Joaquin
    Griggs, Nicholas
    Nastase, Anthony
    Anand, Jessica
    Jutkiewicz, Emily J.
    Mosberg, Henry
    Traynor, John
    FASEB JOURNAL, 2018, 32 (01):